Skip to content
lifestyle.marketresearchjournals.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
InflaRx N.V.
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
May 23, 2026
InflaRx to Report First Quarter 2026 Results on May 7, 2026
May 23, 2026
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 22, 2026
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
April 9, 2026
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
March 31, 2026
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
March 18, 2026
InflaRx to Report Full Year 2025 Results on March 19, 2026
March 12, 2026
←
Previous Page
1
2